Primary central nervous system CD20-negative diffuse large B-cell lymphoma: A case report

DOI: https://doi.org/10.21203/rs.3.rs-1665565/v1

Abstract

Background: CD20-negative diffuse large B-cell lymphoma is a very rare and heterogeneous invasive cancer characterized by chemical resistance and poor prognosis. Primary CD20-negative diffuse large B-cell lymphoma of the central nervous system is even rarer, presenting great challenges in pathological diagnosis and clinical treatment.

Case Presentation: We report a case of primary CD20-negative diffuse large B-cell lymphoma of the CNS in a 54-year-old woman admitted to the hospital with a headache lasting more than 10 days. CT and MRI scans showed right temporal lobe lymphoma. Microscopically, large infiltrating lymphoid cells that induced brain tissue damage were observed. Immunohistochemistry showed that the tumor cells were CD79a+, PAX-5+, MUM1+, and CD20-. The patient was diagnosed with lymphoma and transferred to an oncology hospital for chemotherapy.

Conclusions: To the best of our knowledge, this is one of the first reported cases of unclassifiable CD20-negative diffuse large B-cell lymphoma located in the CNS. This case report aims to deepen the understanding of clinicopathological features of this type of lymphoma and expand the scope of this disease.

Introduction

Primary central nervous system (CNS) lymphoma is a relatively rare, highly aggressive malignant tumor that accounts for approximately 1–2% of non-Hodgkin’s lymphoma. Of this percentage, diffuse large B-cell lymphoma (DLBCL) is the most common type of CNS lymphoma, accounting for about 84.6% of these cases[1, 2]. Approximately 98% of DLBCL cases express the B cell antigen marker, CD20[3]. Of those patients, approximately, 76% will benefit from the rituximab + CHOP regimen. However, 1–2% of DLBCL cases do not express CD20 and are resistant to rituximab treatment. Furthermore, these cases are often accompanied by chemoresistance and extranodal organ invasion, resulting in a poor prognosis[4].

Here, we report the first case of CD20-negative DLBCL originating in the CNS. To improve the diagnostic accuracy of this rare disease, we comprehensively performed histopathological, immunophenotypic, and molecular characterizations. From these observations, an overview is given, and potential differential diagnoses are discussed.

Case Presentation

A 54-year-old female patient was admitted to the hospital due to a headache lasting for more than 10 days. Cranial computed tomography (CT), as well as regular magnetic resonance imaging (MRI) in combination with contrast-enhanced MRI, showed an irregular mass measuring 31×27×20 mm in the right temporal lobe. The contrast-enhanced scan was unevenly enhanced, and a large area of non-enhanced edema involving the basal ganglia was observed. The right lateral ventricle and third ventricle were compressed, and the midline structure was shifted to the left by approximately 9.4 mm. Additionally, the presence of right temporal lobe lymphoma or metastases was assessed (Fig. 1). Cranial functional magnetic resonance spectroscopy (MRS) indicated that the right temporal lobe tumor had increased Cho, a decreased Cr peak, a decreased NAA peak, and a maximum Ch/NAA ratio of 4.58. Additionally, MRS indicated that the tumor in the right temporal lobe was prone to malignancy. The PET-CT data indicated that, characteristic of primary brain tumors, the right temporoparietal space-occupying lesions had increased metabolism (SUVmax 25) and large surrounding edema. No obvious areas of increased metabolism were found. Serology assessments revealed that the patient was HIV and HHV-8 negative. Intraoperatively, the tumor was located on the deep surface of the right temporal lobe. The tumor was solid, translucent jelly-like, with clear borders, no capsule, minimal vasculature, and possessed a soft texture. The patient's and family's history was unremarkable.

Gross pathological examination revealed an area of broken gray-white tissue (2.5×2×1 cm) with partial hyperemia, no capsule, and gray-white matter on the cut surface. Under low magnification, the brain tissue was diffusely infiltrated and severely damaged by many large lymphoid cells and no lymphoid follicle structures were observed (Fig. 2A). Additionally, local tumor interstitial microvascular proliferation, tumor cell arrangement around the blood vessels (Fig. 2B), and tumor cell infiltration of the blood vessels intracavity were noted. Under high magnification, the tumor cells were medium to large, round or oval, possessed clear nuclear membranes, displayed different nuclear staining characteristics, were variably vacuolated or possessing of irregular mass, exhibited nucleoli, and had 1 to 3 nucleoli of central or near nuclear membranes, cytoplasmic dichromatic or basophilic cells, centroblast-like and immunoblastic-like cells, and pathological mitotic cells are shown (Fig. 2C). From these morphological data, lymphoma was diagnosed, specifically favoring DLBCL.

Immunohistochemical assays identified the presence of large lymphoid cells by LCA+++, CD79a+ (Fig. 3A), PAX-5+ (Fig. 3B), MUM1+ (Fig. 3C), CD3-, and CD5- staining that, together, are indicative of B cells involvement. Furthermore, the patient’s tissue was CD10-, Bcl-6+, and MUM1+, indicative that the cells did not originate from a germinal center. CyclinD1-, CD5-, SOX-11-, and Bcl-2- staining data indicated that mantle cells and follicular cells likely did not contribute to the current phenotype. The EMA, GFAP, IDH1, P53, O1igo-2, S100, Syn, and CgA marks were all negative, thus excluding central nervous epithelial tumors such as astrocytoma and oligodendroglioma from consideration. Together, due to these data in combination with Ki-67 expression (90% positivity) (Fig. 3D), which is suggestive of active proliferation, the patient was diagnosed with DLBCL.

CD20 and CD21 staining of the tissues was negative. Initially, this result was considered to be a technical error that was introduced during the immunohistochemical analyses. However, upon repetition of the assay, and including a robust positive control, the results showed that the tissue remained CD20 negative (Fig. 3E-F) (the positive control was strongly positive (Fig. 3G)). Additionally, the reactive lymphocytes of the surrounding brain tissue between the tumor were CD20 positive (Fig. 3H), which further excluded any false negatives that may have been present in the tissue-embedded wax block. Combined with morphological features and reliable immunohistochemical indicators, a definitive diagnosis of CD20-negative DLBCL was made.

To clarify the specific lymphoma type, additional immune indicators were assessed. The ALK, CD138, CD38, and EBER/ISH markers were all negative. Additionally, the Bcl-6 and EMA markers came back positive and negative, respectively. Laboratory serology revealed that the patient was HIV and HHV-8 negative. From these observations, the possibility that the current case was EBV-positive LBCL with plasmacytoid differentiation, primary effusion lymphoma (PEL), plasmablastoma (PBL), ALK+ LBCL, or HHV8+ DLBCL, NOS was dismissed. Combined with HE morphological features, these serological results are not consistent with anaplastic DLBCL. Additionally, the patient's medical history was well recorded and no history of tumor and drug use (including rituximab) was present. Therefore, CD20-negative DLBCL with drug-induced CD20 antigen loss was excluded. Next-generation sequencing (NGS) was then used to detect 101 genes related to lymphoma. Of these genes, 11 gene mutations (Table 1), including BTG2, ITPKB, TET2, FAT1, PIM1, CARD11, KMT2C, NOTCH1, KMT2D, SOCS1, and BCORL1 were noted.

Together, these data in combination with the patient's clinical history laboratory tests, HE morphological features, reliable immunohistochemical results, and genetic testing results, the diagnosis was CD20-negative DLBCL of the right temporal lobe. The specific type was noted as being unclassifiable/unclassified. After the patient was diagnosed with lymphoma, he was transferred to the cancer hospital for CHOP chemotherapy. The patient’s condition was stable and they were followed up closely.

Discussion

Most CNS lymphomas are DLBCL. In addition to the histological features of general lymphomas, DLBCL often has notable characteristic histological features such as the presence of medium-to-large lymphoid cells that are distributed around blood vessels that can infiltrate arterioles in a ring-like arrangement. Additionally, spherical or cuff-shaped infiltration of small blood vessels can be observed. Previous studies have shown that this form of cellular infiltration can destroy blood vessels and allow cancerous cells to enter the lumen. In the current case, interstitial tumor cells were accompanied by significant microvascular proliferation and were seen to be distributed in a sleeve-like manner around the blood vessels.

CD20-negative DLBCL is a rare and heterogeneous group of aggressive lymphomas that have been further characterized into 5 sub-categories or types, namely: primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), ALK-positive large B-cell lymphoma, anaplastic lymphoma, lymphoma derived from human herpesvirus 8-related multicentric Castleman disease, and large B-cell lymphoma (HHV8+DLBCL, NOS)[5]. Additionally, plasmacytoid differentiated EBV-positive LBCL and CD20-negative DLBCL following rituximab treatment have also been reported[6]. These heterogeneous lymphomas all have immunoblasts as well as transcriptional profiles that are similar to that of plasma cells, and usually show high invasiveness, chemotherapy resistance, and low survival[5].

In addition to the above four types described above, in EBV-positive LBCL, unspecified (EBV+ DLBCL, NOS) often expresses MUM1, PAX-5, and CD20/CD79a. Furthermore, this sub-type does not express CD10, BCL-6, and CD15; and greater than 90% of cases may have EB virus infection. Lastly, these cases often exhibit CD20 deletion with marked plasmacytoid differentiation.

Previous studiesreported that approximately 20% of CD20+ lymphomas were completely negative for CD20 after R-CHOP treatment, and that 6% were partially negative for CD20[6, 7]. It is possible that Rituxan selectively attacks and destroys CD20+ tumor cells, resulting in the predominant proliferation of CD20- tumor cells. Alternatively, the saturation of the concentration of Rituxan in serum may result in false negatives[8].

At the gene level, DLBCL cases are divided into two major molecular subtypes, germinal center B-cell-like (GCB) and activated B-cell-like (ABC). Additionally, there are a small number of unclassifiable sub-types according to specific, distinct gene expression profiles and cellular origins. With the development of gene sequencing technologies, more subtypes have been discreetly identified. The mechanism of CD20 deletion is extremely complex. Studies have shown that CD20 deletion in CD20-negative DLBCL is associated with gene changes and abnormal regulation, such as the deletion of the CD20-encoding gene, MS4A1[9], FXPO1, and other related transcription factors [10]. Furthermore, alterations to the ubiquitin-protease system have also been implicated to contribute to CD20-negative DLBCL[11]. In the current case, using next-generation sequencing, 11 gene mutations were identified. These included BTG2, ITPKB, TET2, FAT1, PIM1, CARD11, KMT2C, NOTCH1, KMT2D, SOCS1, and BCORL1. Consistent with the findings presented by Fukumura[12], hypermutation of the BTG2 and PIM1 genes in DLBCL of primary CNS was observed. Additionally, NOTCH1 and KMT2D gene mutations were observed. These findings were consistent with the N1 typing data reported by Schmitz[13]. Based on classification data proposed by Lacy[14], the TET2 and SOCS1 gene mutations observed in the current study indicated that this DLBCL should be classified into an unclassified group other than the 5 described above. Enhanced mutations within the CARD11 gene in the EZB-MYC-group were previously reported by George[15]. In agreement with mutations observed in tumors by Agata[16], mutations in the BCORL1 and TET2 genes were also observed. The gene and molecular heterogeneity of DLBCL are large, and few studies have investigated CD20-negative DLBCL-associated genetic mechanisms. Thus, the currently unclassifiable CD20-negative DLBCL disease pedigree and the mechanism of CD20 deletion need to be further expanded and confirmed.

In the current case, the above subtypes of DLBCL were excluded from the diagnosis based on the clinical history, laboratory examination, histomorphological characteristics, and immunohistochemical results. The current case cannot be classified based on existing criteria, and as it occurred in the central nervous system, is extremely rare. Unclassifiable cases of CD20-negative DLBCL have been reported in foreign literature[17–19]; however, these unclassifiable cases have unique clinicopathological features. The current case is the first case of CNS and unclassifiable CD20-negative DLBCL.

In terms of treatment, the type of DLBCL has no target for rituximab due to CD20 deletion and is prone to chemotherapy resistance. Currently, a single CHOP regimen is used in clinical chemotherapy; however, the disease progresses rapidly and the prognosis is poor. Some scholars[20] have assessed the ESHAP regimen, high-dose liposomal doxorubicin + cyclophosphamide + vincristine + methylprednisolone chemotherapy, however, the effects were not satisfactory. The NCCN recommends that radiotherapy combined with second-line treatment such as bendamustine, lenalidomide, and other drugs can be tried, however, no reported benefit has been published to date.

Conclusion

In conclusion, CD20-negative DLBCL is rare and presents significant challenges in both diagnosis and treatment. In terms of diagnosis, clinical history, laboratory examinations, histomorphological characteristics, reliable immunohistochemical results, and more accurate immune marker examination techniques should be combined to robustly improve diagnosis. Additionally, the disease pedigree still needs to be further expanded. In terms of treatment, due to CD20 deletion, it is impossible to benefit from rituximab target therapy, and chemotherapy resistance is common. Novel treatment strategies that are based on a comprehensive understanding of the genetic mechanisms of unclassified DLBCLs are urgently required.

Abbreviations

CT: Computed tomography; MRI: Magnetic resonance imaging; PET-CT：Positron Emission Tomography-Computed Tomography; NGS:next-generation sequencing; NCCN:National Comprehensive Cancer Network.

Declarations

Ethics approval and consent to participate 

This case report was approved by the Ethics Committee of the Affiliated Hospital of Zunyi Medical University. Written informed consent was obtained from the patient for publication of this clinical case report.

Consent for publication 

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Availability of data and materials 

All the data regarding the findings are available within the manuscript.

Competing interests 

The authors declare that they have no competing interests.

Funding

None

Authors’ contributions 

Resources: Shuai Luo, Xiang Huang, Yao Li, Writing–original draft: Shuai Luo. Writing & editing:Shuai Luo, Jinjing Wang. All the authors have read & approved the final manuscript.

Acknowledgements 

The authors would like to thank all the reviewers who participated in the review and MJEditor (www.mjeditor.com) for its linguistic assistance during the preparation of this manuscript.

References

  1. Deckert M, Engert A, Brück W, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma[J]. Leukemia, 2011, 25(12): 1797–807.
  2. Tang D, Chen Y, Shi Y, et al. Epidemiologic Characteristics, Prognostic Factors, and Treatment Outcomes in Primary Central Nervous System Lymphoma: A SEER-Based Study[J]. Front Oncol, 2022, 12: 817043.
  3. Boyd S D, Natkunam Y, Allen J R, et al. Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results[J]. Applied immunohistochemistry & molecular morphology: AIMM/official publication of the Society for Applied Immunohistochemistry, 2013, 21(2): 116.
  4. Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group[J]. The lancet oncology, 2011, 12(11): 1013–1022.
  5. Li J, Zhao S, Wang J, et al. CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases[J]. Tumour Biol, 2016, 37(3): 3619–37.
  6. Maeshima A M, Taniguchi H, Fujino T, et al. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy[J]. Annals of Hematology, 2020, 99: 2141–2148.
  7. Maeshima A M, Taniguchi H, Fukuhara S, et al. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy[J]. The American journal of surgical pathology, 2013, 37(4): 563–570.
  8. Hato T, Yamanouchi J, Tamura T, et al. Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia[J]. International journal of hematology, 2004, 80(1): 62–66.
  9. Maeshima A M, Taniguchi H, Fujino T, et al. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy[J]. Ann Hematol, 2020, 99(9): 2141–2148.
  10. Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy[J]. Haematologica, 2020, 105(6): 1494–1506.
  11. Czuczman M S, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels[J]. Clin Cancer Res, 2008, 14(5): 1561–70.
  12. Fukumura K, Kawazu M, Kojima S, et al. Genomic characterization of primary central nervous system lymphoma[J]. Acta Neuropathol, 2016, 131(6): 865–75.
  13. Schmitz R, Wright G W, Huang D W, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma[J]. N Engl J Med, 2018, 378(15): 1396–1407.
  14. Lacy S E, Barrans S L, Beer P A, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report[J]. Blood, 2020, 135(20): 1759–1771.
  15. Wright G W, Huang D W, Phelan J D, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications[J]. Cancer Cell, 2020, 37(4): 551–568.e14.
  16. Bogusz A M. EBV-Negative Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder with Marked Morphologic Pleomorphism and Pathogenic Mutations in ASXL1, BCOR, CDKN2A, NF1, and TP53[J]. Case Rep Hematol, 2017, 2017: 5083463.
  17. Abdullgaffar B, Seliem R M. De Novo Unclassifiable CD20-negative diffuse large B-cell lymphoma: a diagnostic and therapeutic challenge[J]. International journal of surgical pathology, 2018, 26(3): 266–270.
  18. Gaur S, Padilla O, Nahleh Z. Clinical features and prognosis of CD20 negative aggressive B-cell non-Hodgkins lymphoma[J]. Lymphoma, 2013, 2013.
  19. Garg M, Lee B E, Mcgarry K, et al. CD 20-negative diffuse large B‐cell lymphoma presenting with lactic acidosis[J]. American journal of hematology, 2015, 90(3): E49-E50.
  20. Lu Y, Gao X, Fang M. [CD20-negative primary intestinal diffuse large B-cell lymphoma:a case report and literature review][J]. Zhonghua Xue Ye Xue Za Zhi, 2015, 36(5): 430–2.

Tables

Table 1 is available in the Supplemental Files section.